MANUFACTURERS

PDR Network services are the most comprehensive, effective and cost-efficient means to distribute FDA-approved drug information, updates, patient safety communications, IND notifications, recalls and REMS programs to U.S. prescribers.

How do manufacturers use PDR Network?

Nearly all pharmaceutical companies use PDR Network services to distribute drug information and urgent product safety Alerts electronically via the PDR Drug Alerts Network.  This includes distribution via print and electronic channels, as well as directly via electronic health record platforms. This is in full accordance with the FDA’s 2006 guidance to manufacturers, which states that electronic Alert systems like those offered by PDR are preferable for delivering these Alerts.

How does this service help manufacturers protect patient safety?

PDR Network improves patient safety and protects the interests of consumers and healthcare providers through delivery of comprehensive pharmaceutical product information, updated regularly, together with time-sensitive communication on important product safety developments in print and electronic formats and directly via EHR systems.  This unique combination of services fulfills duty-to-warn and FDA requirements and offers healthcare providers a single resource for all important product information and updates.

How does PDR Network support the FDA’s new Risk Evaluation and Mitigation Strategies (REMS) requirements of pharmaceutical firms?

REMS and other risk communication represent substantial and growing challenges for pharmaceutical manufacturers. Among these challenges is the need to successfully engage and communicate with prescribers and dispensers, and a communication strategy is a central requirement in every REMS program. PDR Network provides leading industry expertise in the development and execution of REMs programs – including CME and patient education – and offers a powerful distribution channel for rapidly and inexpensively distributing REMS programs to physicians and other prescribers.

Manufacturer Advisory Committee

Ms. Andrea Masciale (Johnson & Johnson Pharmaceuticals Group)
Dr. Robert Hoff (Abbott Laboratories, Inc.)
Dr. Edward Fotsch (PDR Network)
Ms. Theresa Matkovits (The Medicines Company)
Mr. Edward Collins (GlaxoSmithKline)
Dr. Dina Anand (Johnson & Johnson Pharmaceutical Research & Development)
Mr. Jeffrey Secunda (AdvaMed)
Dr. Barbara Rullo (sanofi-aventis)
Mr. Andrew Emmett (Biotechnology Industry Organization)
Ms. Joanne Machalaba (Novartis Pharmaceuticals Corporation)
Dr. Gary Appio (Novartis Pharmaceuticals Corporation)
Dr. Alan Lembitz - Chair (COPIC Insurance Company)
Dr. Steven Merahn (PDR Network)